A phase 2a clinical trial of NEO100-01 is continuing to recruit patients with ... Sequencing the novel drug, THIO, with Libtayo tended to be tolerable in patients with non-small cell lung cancer, ...

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945's potential as a monotherapy or in combination with the second-line immunotherapy Libtayo.

Senhwa Biosciences, Inc., a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, announced that the completion of Clinical Study ...

Dr Israel Lowy, senior vice president of translational and clinical sciences in ... and vice-chair of the Trial Steering Committee, commented: “Libtayo is an important advancement for patients ...

showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at the combination of BNT111 with Regeneron's PD-1 inhibitor Libtayo (cemiplimab ...

April 02, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical ... with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial ...

Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic ...

That's one reason to look into clinical trials, where researchers test new ... You may take cemiplimab (Libtayo), nivolumab (Opdivo), or pembrolizumab (Keytruda). Atezolizumab (Tecentriq ...

CRISPR-Cas9 treatments, aimed at genetic disorders, have over 1,200 clinical trials ongoing ... Key products like EYLEA, Libtayo, and Dupixent propelled the company’s growth.

Oncology drug Libtayo exceeded $1 billion in sales for ... GSK to Acquire IDRx, Inc. GSK plc GSK announced an agreement to acquire clinical-stage private biotech IDRx, which makes precision ...

This trial is particularly noteworthy as it evaluated CX-4945 monotherapy in patients who had already failed first-line HHIs. Notably, 27.3% (6 patients) had also failed second-line PD-1 inhibitors ...